Patil Vijay M, Joshi Amit, Noronha Vanita, Talreja Vikas, Simha Vijai, Dhumal Sachin, Bandekar Bhavesh, Chandrasekharan Arun, Prabhash Kumar
Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India.
South Asian J Cancer. 2019 Jul-Sep;8(3):173-177. doi: 10.4103/sajc.sajc_230_18.
Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma nasopharynx and studied their outcomes.
Patients who underwent first-line palliative systemic chemotherapy between January 2014 and April 2017 for carcinoma nasopharynx at the department of medical oncology at authors' institute were selected for this analysis. Toxicities, responses, progression-free survival (PFS), and overall survival (OS) were analyzed. In addition, a Quality-Adjusted Time without Symptoms or Toxicity analysis with threshold utility analysis was performed.
Fifty-one patients were included in this analysis. The indication of palliative chemotherapy was locoregionally recurrent disease in 25 (49.0%) patients and metastatic disease in 26 (51.0%) patients. The overall response rate was 62.0% ( = 33). The median PFS was 225 days (95% confidence interval [CI]: 164-274 days) and median OS was 513 days (95% CI: 286-931 days). The restricted mean TOX state duration was 2.6 days (95% CI: 0.3-4.9), restricted mean TWiST duration was 219.2 days (95% CI: 184.0-254.4), and restricted mean REL duration was 74.3 days (95% CI: 38.1-110.4).
Systemic cytotoxic therapy in nasopharyngeal cancers is associated with high response rates and clinically meaningful PFS; with low duration of time spent in adverse events.
鼻咽癌是一种罕见的恶性肿瘤。我们对鼻咽癌姑息治疗中接受的全身治疗进行了一次审核，并研究了其治疗效果。
选取2014年1月至2017年4月期间在作者所在机构肿瘤内科接受一线姑息性全身化疗的鼻咽癌患者进行分析。分析毒性、反应、无进展生存期（PFS）和总生存期（OS）。此外，还进行了无症状或毒性的质量调整时间分析以及阈值效用分析。
本分析纳入了51例患者。姑息化疗的指征为局部区域复发性疾病25例（49.0%），转移性疾病26例（51.0%）。总缓解率为62.0%（n = 33）。中位PFS为225天（95%置信区间[CI]：164 - 274天），中位OS为513天（95% CI：286 - 931天）。受限平均毒性状态持续时间为2.6天（95% CI：0.3 - 4.9），受限平均无病生存期持续时间为219.2天（95% CI：184.0 - 254.4），受限平均疾病相关生存期持续时间为74.3天（95% CI：38.1 - 110.4）。
鼻咽癌的全身细胞毒性治疗与高缓解率和具有临床意义的PFS相关；不良事件持续时间较短。
